Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.
A live and archived webcast will be available in the Investors > Events section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – IRD
In the May 27 session, IRD gained 1.22%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Conference appearance | Neutral | -2.9% | RBC Global Healthcare Conference presentation announcement for May 19, 2026. |
| May 12 | Earnings and update | Neutral | +1.2% | Q1 2026 results with cash runway, losses, and pipeline timelines. |
| May 07 | Clinical data update | Positive | -6.9% | ARVO 2026 data showing early functional gains in IRD programs. |
| May 07 | Trial enrollment | Positive | +1.9% | Completion of Cohort 1 enrollment in OPGx‑BEST1 Phase 1/2 study. |
| May 04 | Regulatory program | Positive | -0.4% | FDA acceptance of OPGx‑LCA5 into the RDEP program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory updates often saw muted or negative next-day moves, while operational updates like trial enrollment and earnings sometimes aligned modestly with the news tone.
Over the past month, Opus Genetics has reported multiple milestones. On May 4, FDA RDEP acceptance for OPGx‑LCA5 was announced. On May 7, the company completed enrollment in Cohort 1 of its OPGx‑BEST1 Phase 1/2 study and shared ARVO 2026 data showing functional gains. Q1 2026 financials and a corporate update followed on May 12, and an RBC conference appearance was announced on May 13. Today’s Jefferies conference appearance continues this pattern of active investor outreach rather than a new clinical or financial catalyst.
Key Terms
gene therapies medical
inherited retinal diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
